Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets

Panisinee Lawasut, Richard W J Groen, Eugen Dhimolea, Paul G Richardson, Kenneth C Anderson, Constantine S Mitsiades

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

In recent years, significant progress has been achieved in the characterization of the transcriptional profiles, gene mutations and structural chromosomal lesions in myeloma cells. These studies have identified many candidate therapeutic targets, which are recurrently deregulated in myeloma cells. However, these targets do not appear, at least individually, to represent universal driver(s) of this disease. Furthermore, evaluation of these recurrent lesions does not suggest that they converge to a single molecular pathway. Detailed integration of molecular and functional data for these candidate targets and pathways will hopefully dissect which of them play more critical roles for each of the different individual molecular defined subtypes of this disease. This review focuses on how recent updates in our understanding of myeloma pathogenesis and molecular characterization may impact ongoing and future efforts to develop new therapeutics for this disease.

Original languageEnglish
Pages (from-to)537-48
Number of pages12
JournalSeminars in Oncology
Volume40
Issue number5
DOIs
Publication statusPublished - Oct 2013

Cite this